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Research article

Type 3 deiodinase is critical for the maturation
and function of the thyroid axis
Arturo Hernandez,1 M. Elena Martinez,1 Steven Fiering,2 Valerie Anne Galton,3
and Donald St. Germain1,3
1Department

of Medicine, 2Department of Microbiology and Immunology, and 3Department of Physiology,
Dartmouth Medical School, Lebanon, New Hampshire, USA.

Developmental exposure to appropriate levels of thyroid hormones (THs) in a timely manner is critical to
normal development in vertebrates. Among the factors potentially affecting perinatal exposure of tissues to
THs is type 3 deiodinase (D3). This enzyme degrades THs and is highly expressed in the pregnant uterus, placenta, and fetal and neonatal tissues. To determine the physiological role of D3, we have generated a mouse
D3 knockout model (D3KO) by a targeted inactivating mutation of the Dio3 gene in mouse ES cells. Early in
life, D3KO mice exhibit delayed 3,5,3′-triiodothyronine (T3) clearance, a markedly elevated serum T3 level, and
overexpression of T3-inducible genes in the brain. From postnatal day 15 to adulthood, D3KO mice demonstrate central hypothyroidism, with low serum levels of 3,5,3′,5′-tetraiodothyronine (T4) and T3, and modest
or no increase in thyroid-stimulating hormone (TSH) concentration. Peripheral tissues are also hypothyroid.
Hypothalamic T3 content is decreased while thyrotropin-releasing hormone (TRH) expression is elevated. Our
results demonstrate that the lack of D3 function results in neonatal thyrotoxicosis followed later by central
hypothyroidism that persists throughout life. These mice provide a new model of central hypothyroidism and
reveal a critical role for D3 in the maturation and function of the thyroid axis.
Introduction
Thyroid hormones (THs) are essential for normal vertebrate development. In mammals, including humans, precise levels of THs
during fetal and neonatal life are critical for appropriate cell proliferation and differentiation (1). Reduced or excessive THs during
these developmental stages can result in severe abnormalities (2,
3). Particularly dramatic is the observation of important alterations in the maturation and function of the CNS in mammals with
congenital hypothyroidism (2, 3). Some of the important actions
of THs during development occur at a time when TH levels are
much lower than those in the mother (4, 5) and the hypothalamicpituitary-thyroid (HPT) axis is not fully functional.
Type 3 deiodinase (D3), a conserved selenoprotein coded by the
Dio3 gene, is responsible in part for the low TH levels in the fetus.
Dio3 is subject to genomic imprinting and is preferentially expressed
from the paternal allele in the mouse fetus (6, 7). D3 catalyzes the
conversion of the hormones secreted by the thyroid, the active
hormone 3,5,3′-triiodothyronine (T3) and prohormone 3,5,3′,5′tetraiodothyronine (T4), into biologically inactive metabolites by
removing an iodine atom from the tyrosyl ring of both compounds
to form 3,3′-diiodothyronine (3,3′-T2) and 3,3′,5′-triiodothyronine
(reverse T3) (8, 9). Thus, D3 is an inactivator of THs and serves as a
modulator of intracellular TH levels and TH action.
In rodents, D3 activity is abundant in the pregnant uterus and
placenta (10–13) and most fetal tissues (14), including the CNS
(15). In contrast, during late neonatal and adult life, D3 activity
is more limited, being significant in the skin (16) and central nerNonstandard abbreviations used: D3, type 3 deiodinase; HPT, hypothalamic-pituitary-thyroid; neo-T4, neonatal T4; reverse T3, 3,3′,5′-triiodothyronine; S14, spot 14;
T3, 3,5,3′-triiodothyronine; T4, 3,5,3′,5′-tetraiodothyronine; TH, thyroid hormone;
TRH, thyrotropin-releasing hormone; TSH, thyroid-stimulating hormone.
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vous system (15, 17, 18), detectable in certain endocrine organs
(18), and very low or absent in other tissues.
Though the physiological significance of D3 is unknown, its
biochemical function and tissue expression pattern suggest that it
plays a role in protecting tissues, particularly those in the developing fetus, from inappropriate levels of THs. This is of particular
importance as fetal serum levels of THs in the rat are only 5% of
those present in the mother (19). As the HPT axis matures during late gestation and the neonatal period, serum TH levels rise
steadily and reach values comparable to those in the adult in the
second week of life (5, 19).
In order to characterize the physiological relevance of D3, we
have disrupted the gene coding for D3 in mouse embryonic stem
cells and generated a D3 KO mouse (D3KO) with no detectable
D3 activity. The D3KO mouse manifests marked abnormalities in
thyroid status and physiology, underscoring the critical role of this
enzyme in the development and function of the HPT axis.
Results
Neonatal hypothalamic D3 expression. To understand the potential role
of D3 in the developing HPT axis, we first determined D3 activity in
the mouse hypothalamus during neonatal life. We observed a high
level of expression during the first week of life, with a marked diminution immediately thereafter (Figure 1). This pattern is similar to
that described in the rat (20) and suggests a role for D3 in limiting
hypothalamic exposure to THs during early development.
Generation of D3-deficient mice. We have recently described a successful strategy utilizing homologous recombination in mouse ES
cells for disruption of the Dio3 gene (6). The neomycin cassette
used for positive selection of recombinant ES cells was excised with
appropriate breeding with a Cre-expressing mouse as described in
Methods. After this excision, the final structure of the mutated
Dio3 locus is illustrated in Figure 2A. The mutant mice carry a
triple point mutation affecting 2 codons, one of them coding for
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Figure 1
Neonatal hypothalamic D3 activity. Each point represents the mean ±
SEM of determinations in 4 animals.

selenocysteine, an active site residue that is critical for enzyme
function (8, 21). That this construct codes for an inactive enzyme
was shown by transfection experiments in COS-7 cells (data
not shown), indicating that the mutation completely abolished
enzyme activity. In addition to the triple mutation, mutant mice
carry a residual insertion of a loxP site, 34 bp in length, located in
the 3′-untranslated region. The presence of this insertion was used
for routine genotyping as illustrated in Figure 2B.
This targeting strategy was designed to fully inactivate D3 while
at the same time producing a minimal disruption in the Dio3 locus.
This is critically important for 2 reasons. First, this locus is imprinted and belongs to a larger imprinted domain in which long-range
mechanisms may control gene expression (22, 23). Second, an additional gene, termed Dio3os, is expressed from the opposite DNA
strand and features multiple transcripts that result from alternative
splicing (6, 24). The full structure and function of the Dio3os gene
have not yet been determined, but partial exonic sequences from
a specific Dio3os transcript lie within the Dio3 exon and promoter,
5′ to the point mutations and the residual loxP site (24).
Thus, a large deletion in the Dio3 locus might result in unwanted
effects in gene expression within this imprinted region or in the
disruption of Dio3os gene expression. To confirm that this was
not the case, we performed Northern blot analysis to determine
Dio3os mRNA expression in fetuses homozygous for the Dio3
mutation. As shown in Figure 2C, there is no noticeable change in
the pattern of Dio3os transcripts, suggesting that the small modifications introduced in the Dio3 locus do not disrupt the expression of Dio3os transcripts in these mice. This is consistent with
our previous observations that no Dio3os transcripts are detected
by Northern blot analysis when using as a probe a genomic fragment comprising the Dio3 3′-untranslated region (24), where the
residual loxP site is located. Although it is uncertain whether the
triple point mutation introduced in the Dio3 coding region lies
within exonic sequence of the Dio3os gene, this mutation would
not disrupt any of the potential open reading frames coding for a
hypothetical Dio3os protein.
D3 activity is undetectable in D3KO mice. Unless stated otherwise, all
the WT and D3KO animals (homozygous for the mutated allele)
used in the present work were born to heterozygous mothers of the
129/Sv strain. D3 activity in WT and D3KO mice was determined

in various tissues known to express D3, such as the pregnant uterus, placenta, adult midbrain, cerebral cortex and ovary and in E14.5
whole fetuses (Table 1). As expected, no D3 activity was detected in
tissues from D3KO mice except in the placenta. Low levels of D3
activity (2.5% of that in the WTs) were measured in the placentas
of D3KO fetuses that were conceived by heterozygous mothers.
This can be attributable to the presence in the tissue of a residual
cell population of maternal origin that expresses D3. Indeed, no
placental D3 activity was found in D3KO fetuses that were carried
by D3KO mothers (Table 1). These results demonstrate that the
introduced mutation completely inactivates the D3.
General phenotype of the D3KO mouse. The proportion of D3KO
pups obtained from heterozygous matings was lower than the 25%
expected from Mendelian laws. Out of 349 newborns produced
from heterozygous parents, only 61 (17.5%) were D3KO (P = 0.05).
This observation suggests partial lethality of D3KO mice that
occurs at or before the time of birth. D3-deficient mice also exhibited impaired reproductive function. Fertility rates were very low
in D3KO mice of both sexes. In addition, both male and female
D3KO mice were markedly growth retarded (Figure 3). This retardation was already apparent at weaning, when their weight was
only 65% of that of the WT mice. This reduction in size persists
into adulthood and is still observed in 1-year-old animals (data not
shown). Body length is approximately proportional to weight, as
shown in the picture included in Figure 3. This general phenotype,
with slight variations, is observed in 129/Sv, C57BL/6, and mixed
129/Sv/C57BL/6 genetic backgrounds.
Weanling and adult D3KO mice manifest central hypothyroidism. In the
late postnatal period, D3KO mice were hypothyroid. Compared
with WT mice, the serum T4 level in D3KO weanlings was reduced

Figure 2
Targeting of the Dio3 locus. (A) Diagram of the modified Dio3 exon
after gene targeting and neomycin cassette excision. The triple point
mutation introduced into the D3 catalytic site as well as the location
of the PCR primers P1 and P2 used for genotyping are shown. (B)
Typical results from PCR genotyping of WT, heterozygous (het), and
homozygous mice using the primers P1 and P2. (C) Dio3os mRNA
transcripts expressed in WT and D3KO E15.5 fetuses. Thr, threonine;
Secys, selenocysteine.
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Table 1
D3 activities in different tissues of WT and D3KO mice
Tissue

WT

Pregnant uterus
12402 ± 552
E14.5 fetus
988 ± 92
Adult cortex
1024 ± 42
Rest of adult cerebrum
1066 ± 102
Adult ovary
73 ± 3
Placenta (heterozygous mother)
3070 ± 267
Placenta (D3KO mother)		

D3KO
Undetectable
Undetectable
Undetectable
Undetectable
Undetectable
77 ± 6
Undetectable

D3 activities (fmol/h/mg protein) represent the mean ± SEM. Uterus and
placenta samples correspond to E17.5 gestational age. Adult tissues
were obtained from 3-month-old mice. From 4 to 6 samples were used
for each determination. Undetectable activities in the assay conditions
were lower than 2 fmol/h/mg protein.

by more than 95%, and the serum T3 concentration was reduced
by 50% of normal. However, the serum thyroid-stimulating hormone (TSH) level was unaffected (Figure 4A). In adult D3KO mice,
serum T4 and T3 levels were also low (27% and 80% of those in
WT animals, respectively) while the serum TSH level was elevated
50% (Figure 4B). A very similar pattern of thyroid parameters was
observed in older adults (Figure 4C), indicating that the central
hypothyroidism persists through adult life. The increase in the
TSH level in adults was much lower than what would be anticipated, given the low circulating levels of THs. As a comparison,
a 90-fold increase in TSH concentrations has been observed in
mice in which comparably low TH levels were induced by feeding
a low-iodine diet containing propylthiouracil (25). This failure
of the serum TSH level to be elevated appropriately in the face of
low circulating T4 and T3 levels points to a central etiology of the
hypothyroidism. Values for T3 uptake were comparable in WT and
D3KO mice, 60.1 ± 1.2 and 60.7 ± 1.2, respectively, suggesting that
free fractions of T4 and T3 are the same in the 2 strains.
These low serum TH levels observed in adult D3KO mice
resulted in tissue hypothyroidism. Thus, hepatic expression of
TH-inducible genes such as spot 14 (S14) (26) and type 1 deiodinase (D1) (27) was significantly decreased. Liver S14 mRNA
expression was reduced by more than 80% in D3KO mice, both in
adults and weanlings (Figure 5A). D1 activity and mRNA were also
diminished in D3KO weanlings (Figure 5B).
Perinatal D3KO mice are thyrotoxic. In contrast to the hypothyroidism present in adult mice, D3KO neonates were thyrotoxic,
based on a markedly elevated serum T3 level. At P5, the serum
T3 level in D3KO mice was elevated 4-fold compared with that
of WT animals (Figure 6A). By P10, the serum T3 level in WT and
D3KO mice was comparable, and then, during the next 11 days of
life, D3KO mice transitioned to the hypothyroid state observed in
weanlings and adults. Thus, at P15, the serum T3 level in D3KO
mice was significantly lower (Figure 6A) and by day 21 was only
50% of that observed in WT mice. It is notable that throughout the same period, serum T4 levels in D3KO mice were barely
detectable and much lower than in WT mice (Figure 6B). In WT
mice, the serum T4 level increased steadily during neonatal life to
reach a peak around P15. No such neonatal T4 surge occurred in
D3-deficient animals.
D3KO mice were also thyrotoxic in utero and at the time of
birth; compared with WT mice, E19.5 D3KO fetuses and 1-dayold neonates showed a several-fold elevation in the serum T3 level
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(Figure 6A). At these stages, serum T4 levels were undetectable
(<0.15 µg/dl) in both mutant and WT mice (Figure 6B).
Neonatal serum TSH was markedly suppressed in D3KO mice. In
WT animals, serum TSH values (in mU/l) were 76.8 ± 13.5 (n = 8),
47.3 ± 7.7 (n = 7), and 30.5 ± 8.0 (n = 5) at P5, P10, and P15, respectively. In contrast, serum TSH in D3KO mice at the same ages was
undetectable (<10 mU/l in the assay, n = 5, 3, and 3 animals in each
age group, respectively). Figure 6C summarizes the changes in thyroid parameters that occurred in D3KO mice through 90 days of
age, expressed as a percentage of the values determined in WT animals. This panel shows 3 phases in the abnormalities of the D3KO
thyroid axis. D3KO mice were thyrotoxic early in life with markedly
elevated serum T3 and suppressed serum T4 and TSH. At day P15,
a pattern of central hypothyroidism is apparent with low T4, T3,
and TSH. After weaning and into adulthood, TSH became mildly
elevated though the central hypothyroidism persisted.
To gain further insight into the cause of the high T3 levels
observed during the perinatal period in D3KO mice, we evaluated
the rate of T3 clearance from the serum. WT and D3KO 2-dayold pups were injected with a tracer amount of [125I]-T3, and the
[125I]-T3 present in the blood was measured at different times. Two
hours after injection, the level of [125I]-T3 in the serum of D3KO
pups was double that in the WT mice (Figure 7A). Seven hours
after injection, [125I]-T3 had decreased significantly in WT pups
but very little in the D3KO pups. From the slopes of the curves,
we estimated that D3KO newborns exhibited a significant reduction in the serum T3 clearance rate. Serum [125I]-T3 in WT mice
decreased approximately 5 times faster than in D3KO animals.
Small amounts (<5% of the total) of other radioactive metabolites
were noted in the serum of injected animals. In addition, values
for serum T3 uptake were comparable in WT and D3KO mice at
P2 (Figure 7B), suggesting no difference in serum binding of T3
between the 2 strains. Thus D3KO neonates demonstrate a diminished T3 clearance, and this likely plays an important role in the
high serum level of T3 observed at this age.
Brain thyrotoxicosis in D3KO neonates. To determine the effects on
the brain of the elevated serum T3 level during the neonatal peri-

Figure 3
Postweaning growth curves of WT and D3KO male mice. Each point
represents the mean ± SEM of measurements recorded in 7 to 58
animals at each age. Mean and median group size per data point were
18 and 12, respectively. Only data from animals born in litters of 3 to 7
pups are included. Data from extremely growth retarded D3KO mice,
which typically do not survive through weaning, are not included. A
picture of representative WT and D3KO weanlings is shown. Body
length appear to be proportional to body weight.
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Figure 4
Thyroid status of D3KO mice. Serum T4, T3, and TSH levels in
(A) weanlings (21 days old), (B) adults (90 days old), and (C) older
adults (8 to 13 months old). Number of animals tested are indicated
in parentheses. Bars represent the mean ± SEM. †P < 0.05; #P < 0.01;
*P < 0.0001, WT versus D3KO.

into the active hormone T3 (8, 9). D2 protects the brain from low
levels of THs, and its activity is markedly increased when T4 levels are low (8, 30). In the present study, the profile of D2 activity
in the brain of D3KO mice was consistent with the observed low
serum T4 level. Thus, D2 activity was significantly elevated in the
cerebral cortex of D3KO mice on P5 (Figure 8D) and was dramatically elevated (10- to 15-fold higher than in WT mice) from P10
to P21. A significant increase in D2 activity was also found in the
adult cortex at P90.
Thyrotropin-releasing hormone expression and hypothalamic T3 content.
To investigate the nature of the central hypothyroidism found in
weanlings and adult D3KO mice, we measured hypothalamic T3
content and thyrotropin-releasing hormone (TRH) mRNA expression. At 15 days of age, no difference was observed in the T3 content of the hypothalamus between WT and D3KO mice (Figure
9A). However, a moderate but significant decrease in the T3 content was observed in the hypothalamus of adult D3KO mice. No
difference in TRH mRNA was observed at P15 (Figure 9B), but
TRH expression was elevated in adult D3KO mice, consistent with
the diminished hypothalamic T3 content observed at this age.

od, we analyzed the mRNA expression of RC3 and hairless, 2 genes
that are upregulated by THs in the CNS during the neonatal period (28, 29). In 1- to 3-day-old total brains, hairless expression was
significantly elevated in D3KO animals (Figure 8A). The hairless
mRNA level in the hypothalamus of D3KO mice was also markedly elevated at P5 (Figure 8A). These observations indicate that
the elevated serum T3 level is accompanied by enhanced T3 action
in the neonatal brain. Indeed, the T3 concentration in the brains
of D3KO neonates at P2 was more than double that in WT mice
(Figure 8B). At P3, RC3 mRNA expression was also stimulated in
the brain of D3KO mice as compared with that of WT mice (Figure
8C), but its expression was lower than normal by P15 (Figure 8C),
following the onset of central hypothyroidism. These results indicate that the brain evolves from a thyrotoxic state in the newborn
to a hypothyroid state in late neonatal life, undergoing a transition
in thyroid status analogous to that observed in serum.
An important factor regulating TH action in the brain is type
2 deiodinase (D2), an enzyme that converts the prohormone T4

Discussion
We have found that mice lacking an active D3 exhibit a number of
abnormalities, including partial perinatal mortality, growth retardation, and impaired fertility. D3-deficient neonatal mice also
manifest decreased T3 clearance and striking alterations in serum
and tissue TH levels during perinatal life and adulthood. Thus,

Figure 5
Expression of hepatic T3-inducible genes. (A) Representative Northern blot analysis of liver S14 mRNA in 21-day-old weanlings and
90-day-old adults (top panels) and quantification of S14 mRNA (bottom
panel). 15 mg of total RNA were used. For each sample, the number
of different animals is indicated in parentheses. (B) Expression of D1
mRNA (left panels) and activity (right panel). In Northern blot analysis,
3 mg of poly (A)+ RNA were used. Bars represent the mean ± SEM.
Number of determinations are indicated in parentheses. *P < 0.0001,
WT versus D3KO. Cy, cyclophilin.
The Journal of Clinical Investigation    http://www.jci.org    Volume 116    Number 2    February 2006
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Figure 6
Ontogeny of serum T3, T4, and TSH. (A) Perinatal serum T3 levels.
(B) Perinatal serum T4 levels. T4 levels were undetectable (<0.1 mg/dl)
in E19.5 fetuses and P1 neonates of both genotypes as indicated by
the dotted line. Each point represents the mean ± SEM of determinations in 6 (A) and 7 (B) animals in each group. *P < 0.0001, WT versus
D3KO. (C) Ontogeny of T3, T4, and TSH serum levels expressed as a
percentage of the values in WT animals of corresponding age. Serum
TSH was undetectable in D3KO mice between 5 and 15 days of age
(see text for absolute TSH values).

our findings in this new mouse model indicate that D3 is critical
for both normal development and function of the thyroid axis.
We have shown that the D3KO mouse has no detectable D3
enzymatic activity and that the pattern of transcripts for the
Dio3os gene that is transcribed from the opposite strand at the
Dio3 locus does not appear to be disrupted. Thus, the abnormalities observed in the D3KO mice likely are due solely to the absence
of an active D3 enzyme.
Our observations indicate that the lack of D3 results in a markedly elevated level of T3 in the serum of fetuses and early neonates.
As it is during this developmental stage that D3 expression is at
its highest in the hypothalamus and in most tissues, our results
demonstrate that D3 plays a critical role in maintaining low levels
of THs during fetal and early neonatal life. In the absence of D3,
the clearance of T3 is diminished, and this likely contributes to the
perinatal thyrotoxicosis observed in D3KO mice. In addition to an
increased serum T3 level, increased T3 action in the brain and the
hypothalamus is also observed. In the normal brain, the expression
of various T3-inducible genes increases steadily at a well-defined
rate during neonatal life (31). However, in the D3-deficient newborn, this developmental pattern of expression is disrupted; the
expression of T3-responsive genes is higher than normal at early
neonatal ages and then lower than normal later in development.
The functional consequences of this altered gene expression pattern are as yet undefined but likely to be significant.
The thyrotoxic status in the D3KO newborn evolves to hypothyroidism after 2 weeks of life, and this persists in adulthood.
This is accompanied by tissue hypothyroidism, as demonstrated
by a marked decrease in liver expression of T3-inducible genes. The
480

nature of this hypothyroidism is clearly central, as serum TSH is
suppressed, unchanged, or only slightly elevated in D3KO at different stages despite the low serum concentrations of both T4 and
T3. In the adult, a 50% increase in TSH is observed in the presence
of low T4 and T3 levels. However, this TSH elevation is very modest compared with a model of primary hypothyroidism that shows
similar serum TH levels (25) and where TSH levels are increased
90-fold. This comparison indicates that the hypothyroidism in
D3KO mice is due to central abnormalities of the HPT axis. Indeed,
the TH parameters in the D3KO mouse are remarkably similar to
those observed in the TRH and TRH-receptor KO mouse models
(32, 33), where serum T4 and T3 are decreased and serum TSH is
modestly elevated or unchanged, respectively.
In the adult D3KO mouse, the inability of increased TSH levels
to normalize TH concentrations may reflect a defect in the thyroid
gland. Although this possibility cannot be discarded, preliminary
observations indicate that the size and appearance of the thyroid
gland is normal. A more plausible explanation for the lack of TSH
effect is that TSH bioactivity is diminished. TRH signaling is critical for the proper maturation and glycosylation of TSH (34, 35),
and these posttranslational modifications have been shown to be
necessary for full TSH bioactivity in human cases of central hypothyroidism of hypothalamic origin (36). This has also been shown
in the TRH KO mouse (37).
In considering the etiology of the central hypothyroidism in the
adult D3KO mouse, the rodent model referred to as the neonatal
T4 (neo-T4) syndrome may be of relevance (38, 39). In this model,
the injection of pharmacological doses of T4 (or T3) to rats for 3
to 5 days immediately after birth results in the development of
central hypothyroidism in adults. These animals also show an

Figure 7
Neonatal serum T3 clearance and uptake. (A) [125I]-T3 levels in 2-dayold newborn mice after a single intraperitoneal injection of [125I]-T3 (see
Methods). (B) Percentage of T3 uptake by serum from 2-day-old neonates. Each point represents the mean ± SEM of determinations in 4
(A) and 7 (B) animals in each group. *P < 0.0001, WT versus D3KO.
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Figure 8
Brain expression of T3-regulated genes. (A) Expression of
hairless in the newborn brain and neonatal hypothalamus.
Representative Northern blots are shown, and quantification
of expression was performed in the number of animals indicated in parentheses. Each bar represents the mean ± SEM.
Ribosomal staining or cyclophilin expression was used as a
control to correct for the amount of RNA loaded per lane. (B)
Brain T3 content of P2 newborns. (C) Northern blot analysis of RC3 expression in the brain at P3 and P15. The most
abundant RC3 transcript is shown. (D) Neonatal and adult
brain D2 activity. Each point represents the mean ± SEM of
determinations in 6 animals. *P < 0.0001, WT versus D3KO.

impaired pituitary response to TRH (40, 41). Thus, the neo-T4 rat
model demonstrates that exposure to inappropriately high levels
of THs before the HPT axis is functionally mature results in pituitary and/or hypothalamic abnormalities that affect its regulatory
mechanisms and set point.
Similar observations have been made in humans. Several articles
have described infants who experienced thyrotoxicosis in utero as
a result of poorly controlled maternal hyperthyroidism and who
subsequently developed transient neonatal central hypothyroidism (42, 43). In view of these observations, we suggest that the
main cause of central hypothyroidism in D3KO mice is their overexposure to T3 during a critical period of thyroid axis development. The molecular parameters mediating this occurrence have
not been identified in any of these models.
Notably, the central hypothyroidism observed in D3KO mice is
more severe than that in neo-T4 rats whereas in the human cases
mentioned above, the central hypothyroidism appears to be transient. Although common mechanisms may cause the abnormalities of the HPT axis in the 3 models, the increased severity of the
D3KO phenotype may be due to a higher degree and/or longer

duration of tissue T3 overexposure. In this regard, it
is worth noting that both the neo-T4 rats and human
infants born to hyperthyroid mothers have functional
D3 that may be upregulated in the face of hyperthyroidism (44) and thus partially protect the brain from
exposure to high TH levels. D3KO mice have no such
protective mechanism to ameliorate overexposure to T3.
Hence, a more severe phenotype is not unexpected.
D3KO mice possess intact TRH and TRH-receptor
genes and, indeed, TRH expression is increased in the
adult D3KO hypothalamus, presumably in response
to the demonstrated decrease in T3 content. Thus,
D3 deficiency does not lead to excessive T3 effects
(e.g., suppression of TRH) in the hypothalamus of the
adult D3KO animal. This observation implies that the
mechanism or mechanisms responsible for TSH dysregulation in the D3KO animal differ fundamentally
from that of the TRH KO animal and involve other
molecular changes that alter the set point of TSH secretion
in response to TH feedback. Of interest in this regard is that
THs are known to regulate TRH-receptor mRNA levels in the
pituitary gland, and conceivably this could be part of a develop-

Figure 9
Hypothalamic T3 content and TRH mRNA expression. (A) Hypothalamic T3 content as determined by RIA in hypothalami of 15-day-old
and adult (3-month-old) mice. (B) Quantitation of Northern blot analysis of hypothalamic TRH mRNA levels in 15-day-old and adult mice.
Each bar represents the mean ± SEM of determinations in 5 animals.
*P < 0.001, WT versus D3KO.
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mental program to determine the set point of the thyroid axis
control mechanisms (45).
The thyroid status of the D3KO hypothalamus at P15 does not
reflect the circulating low TH levels; the T3 content of the hypothalamus is not different from that observed in WT mice despite
significant decreases in serum T3 and T4 levels. This is possibly
due to the marked increase in D2 activity or the fact that the brain
is still evolving from a thyrotoxic state and has yet to adjust to
lower serum TH levels. In the adult, however, the thyroid status
of the hypothalamus in the D3KO mouse reflects the hypothyroid serum levels and results in a modest increase in TRH mRNA
expression that qualitatively mimics the situation in WT animals
(46). This finding of a relatively small increase in TRH expression
might be due to the fact that only a fraction of hypothalamic neurons display T3-sensitive TRH expression (45).
Other phenotypic abnormalities observed in the D3KO mouse
include impaired growth, low fertility, and partial perinatal lethality. It is well established that THs exert profound effects on growth
hormone expression (47). Thus, alterations in the growth hormone
axis may play a role in the growth retardation observed in D3KO
mice. Impaired viability in D3KO mice may be due to perinatal
thyrotoxicosis, as a similar observation has been made in rats and
humans (48, 49). Concerning the reproductive function of the
D3KO mouse, severe hypothyroidism may affect fertility in both
sexes, as demonstrated by hyt/hyt mice (50, 51). Of note, fertility
in the TRH KO mouse, which manifests a milder degree of hypothyroidism that is similar to that in the D3KO mouse, is normal
(32). Thus, factors in addition to alterations in adult thyroid status likely play a role in the impaired fertility of the D3KO mouse.
For instance, in utero thyrotoxicosis may also contribute to the
perceived lower fertility of D3KO female mice, as the absence of
a functional maternal D3 in tissues involved in implantation and
placentation may be detrimental to early embryonic viability.
In summary, our results demonstrate that D3 is critical for the
normal development and function of the thyroid axis and plays a
role in maintaining appropriate TH levels in the fetus and neonate.
D3 may be expressed to lower T3 content in this region such that
the thyroid axis set point can develop normally. Beyond the neonatal period, the rapid decrease in D3 activity allows the hypothalamus to more accurately track serum TH levels and thus adjust
TRH expression appropriately.
Although a D3 deficiency has not yet been reported in humans,
the observations in the D3KO mouse predict the occurrence of
central hypothyroidism as part of the phenotype in such cases.
This new model of central hypothyroidism will be valuable for
analyzing the events regulating the maturation and function of
the thyroid axis, as well as the role of D3 and THs in the physiology
of growth, development, and reproduction.
Methods
Generation of D3KO mice. We recently described (6) the strategy used to target
the Dio3 gene using standard homologous recombination techniques. We
utilized the R1 ES cell line (52), which originated from the 129/Sv mouse
strain. Targeted clones were identified by Southern blot analysis, injected
into C57BL/6 blastocysts, and reimplanted in CD1 foster mothers. Chimeric
males that showed germ-line transmission were mated to C57BL/6 females
to test for germ-line transmission of the mutation. Chimeric males were
then mated with 129/Sv females to establish the mutant line in a 129/Sv
background. The neomycin cassette was excised by mating heterozygous
females with a 129/Sv male carrying in chromosome X a transgene express482

ing the Cre DNA recombinase. The removal of the neomycin cassette was
confirmed by Southern blot analysis in the first generation females. The
Cre DNA recombinase transgene was removed from the genetic background of the colony by appropriate matings with WT 129/Sv animals and
sex selection. Animals were kept under a 12-hour light cycle and provided
food and water ad libitum. Animal procedures were approved by the Dartmouth College Institutional Animal Care and Use Committee.
Mice genotyping and serum and tissue sampling. After the removal of the neomycin cassette, genotyping of mice carrying the inactivating mutation was
performed by PCR amplification of the residual loxP site (Figure 1). The
primers used were as follows: 5′-GGAGTCCTGCTGCTTTTGTG-3′ (sense);
5′-CGAGCCTCTCTGCAATTCAG-3′ (antisense). The PCR protocol consisted of 32 cycles that included 20 seconds at 94°C, 20 seconds at 60°C, and
45 seconds at 72°C, with a final extension of 3 minutes. Mouse DNA was
isolated by standard procedures after proteinase K digestion of tail snips.
Animals were killed by asphyxiation with CO2 (adults and weanlings) or
by decapitation (neonates). In the adults and older neonates, blood was
taken from the inferior vena cava while trunk blood was collected from
younger neonates and fetuses. Serum was obtained by centrifugation and
stored at –20°C. For Northern blot analysis and enzymatic activity, tissues
were dissected, immediately frozen on dry ice, and stored at –70°C. Whole
hypothalami were dissected, considering the midbrain and thalamus as the
posterior and dorsal limits, respectively, and the optic chiasm and its ends
as the anterior and lateral limits, respectively.
For the serum determination of T3 clearance, 2-day-old neonates were
injected intraperitoneally with a trace amount of [125I]-T3 (New England
Nuclear) (150,000 cpm, approximately 100 fmol in a volume of 50 µl).
Trunk blood was collected at 2 and 7.5 hours after injection and centrifuged to obtain the serum that was then subjected to paper chromatography to separate T3 from other radioactive metabolites as described (18).
The amount of radioactivity attributable to T3 was determined with a
gamma counter. The clearance rate of T3 in serum was estimated from the
slopes of the lines obtained by plotting the amount of residual [125I]-T3
against the time after injection. The amount of [125I]-T3 injected was not
corrected by body weight, as at 2 days of age the weight of D3KO mice is
within 10% of that in WT animals.
D1, D2, and D3 activities. D1, D2, and D3 enzymatic activities were determined as previously described (18, 44). In brief, tissues were homogenized
in a 10 mM tris-HCl, 0.25 sucrose pH 7.5 buffer. A suitable volume of tissue
homogenate was used in the enzymatic reaction to ensure that deiodination did not exceed 20% and was proportional to the amount of protein
content. Tissue homogenates were incubated at 37°C for an hour with
the appropriate [125I]-labelled iodothyronine (New England Nuclear). For
the D1 assay, 400 nM of reverse T3 in the presence of 2 mM of the cofactor DTT were used. For the D2 assay, we used 1 nM T4 and 20 mM DTT.
For the D3 assay, 2 nM T3 and 20 mM DTT were used. Deiodination was
determined based on the percentage of labeled iodine released (D1 and D2
assays) or the amount of [125I]-3,3′-diiodothyronine produced (D3 assay).
The latter was determined after separation of reaction products by paper
chromatography, as described (53). A factor of 2 was included in the calculations of D1 and D2 activities to correct for the chemical equivalence
of the outer ring iodine residues and the fact that only 1 of them is labeled
in a given molecule.
RNA preparation and Northern blot analysis. Total RNA and poly (A+) RNA
were isolated from mouse liver by guanidine hydrochloride and oligo-dT
cellulose methods, respectively, following standard procedures (54). Total
RNA was isolated from brain tissues using the Ribopure kit from Ambion
Inc. Total and poly (A+) RNA samples were electrophoresed in a denaturing 1% agarose gel containing formaldehyde and blotted onto a Nytran
membrane (Schleicher & Schuell). Blots were hybridized at 42°C in buf-
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fer containing 50% formamide, washed with 0.1X SSC/0.1% SDS at 65°C,
and autoradiographed for 1 to 7 days. Probes were labeled with radioactive
32P-dCTP (ICN Biochemicals Inc.) using the Oligolabelling Kit (Pharmacia Corp.) and were purified through G-50 columns (Pharmacia Corp.).
Quantification of mRNA bands was performed by computer-assisted
densitometry (Molecular Dynamics). The mouse cDNA probes used were
as follows: hairless, a 3-kb BamH1 fragment that includes most of the coding region; RC3, the complete 1.3-kb cDNA; TRH, a 0.8-kb PCR fragment
that includes the coding region; S14, the complete 1.3-kb cDNA; D1, the
complete 1.7-kb cDNA; Dio3os, a mix of 3 partial cDNAs with GenBank
accession numbers AY283182, AY283181, and AY077459.
Hormone determinations. Serum total T4 concentration was determined
using the total T4 Coat-a-Count RIA kit (Diagnostic Systems Laboratories Inc.) according to the manufacturer’s instructions. The sensitivity of
the assay as determined experimentally ranged from 0.1 to 0.2 mg/dl. The
serum T3 level was determined using a sensitive RIA method established
in our laboratory (55) with the modification that the T3 antibody used was
obtained from a commercial source (Fitzgerald Industries International
Inc.). An index of the circulating levels of TH carrier proteins was obtained
by measuring the residual capacity of the serum to bind [125I]-T3, using the
Coat-A-Count RIA T3 uptake kit (Diagnostic Systems Laboratories Inc.)
according to the manufacturer’s instructions. For brain and hypothalamic
T3 determinations, the tissue was weighed and homogenized in 2 ml of
methanol containing 1 mM propylthiouracyl, centrifuged, and the pellet
reextracted twice more. Methanol from the supernatants was collected and
evaporated, the residue resuspended in a buffer containing 0.2 M glycine,
0.13 M sodium acetate, and 0.02% bovine serum albumin, and analyzed by
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